Table 3.

Course of PLA2R antibody during therapy in PLA2R-related disease

VariableMMF (n=15)CP (n=18)P Value
Negative after 2 mo4/911/130.05
Negative after 6 mo6/813/130.06
Negative after 12 mo8/1516/180.02
  • Values are expressed as number of negative samples out of total available samples. MMF, mycophenolate mofetil; CP, cyclophosphamide.